PMID: 18472368
Question: Does treatment duration affect outcome after radiotherapy for prostate cancer?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 18472368
Question: Does treatment duration affect outcome after radiotherapy for prostate cancer?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**

- **Core Content:** The question asks whether the duration of treatment influences the outcomes for patients undergoing radiotherapy (RT) for prostate cancer.
- **Key Information to Identify in the Abstract:**
  - The relationship between treatment duration and patient outcomes.
  - Specific metrics or ratios used to measure treatment duration.
  - Statistical significance of the findings.
  - Any stratification of patients based on risk groups.

**2. Evidence Evaluation**

- **Research Results and Data:**
  - The study involved 1,796 men treated with RT alone for prostate cancer.
  - Treatment duration was measured using the nontreatment day ratio (NTDR).
  - For low-risk patients, those with an NTDR ≥33% had a significantly lower 10-year freedom from biochemical failure (FFBF) rate (57%) compared to those with NTDR <33% (82%), with a p-value of 0.0019.
  - NTDR was independently predictive of FFBF in low-risk patients, even when controlling for other factors.
  - In intermediate and high-risk groups, NTDR was not a significant predictor of outcomes.
- **Strength and Reliability:**
  - Large sample size (1,796 patients) enhances reliability.
  - Statistical significance is established (p-values < 0.05) for low-risk group findings.
  - Multivariate analysis accounts for potential confounders.
- **Relevance to the Question:**
  - The evidence directly addresses the impact of treatment duration (via NTDR) on outcomes after RT for prostate cancer.
  - Although the significant effect is noted primarily in low-risk patients, it supports the notion that treatment duration can affect outcomes in prostate cancer treatment.

**3. Conclusion**

Based on the abstract, treatment duration, as measured by the nontreatment day ratio, negatively affects outcomes in low-risk prostate cancer patients undergoing radiotherapy. While this effect was not observed in intermediate and high-risk groups, the significant impact in the low-risk group provides clear evidence that treatment duration can influence outcomes in prostate cancer treatment.

**4. Final Answer**

**My final choice is: "yes"**
GPT selected: yes

----- Qwen's initial response -----
Qwen is reasoning the answer...

**1. Question Analysis**  
The question asks whether treatment duration (specifically, the duration of external beam radiotherapy) affects outcomes (freedom from biochemical failure, FFBF) in prostate cancer patients. Key information to assess includes the study's definition of treatment duration (via NTDR), the stratification of patient risk groups, and the reported outcomes across these groups.

**2. Evidence Evaluation**  
- **Low-risk group**: The 10-year FFBF was significantly lower (57% vs. 82%, p=0.0019) when NTDR ≥33% (longer treatment duration with more breaks) compared to NTDR <33%.  
- **Intermediate/high-risk groups**: NTDR was not a significant predictor of FFBF.  
- **Multivariate analysis**: NTDR was an independent predictor of FFBF in the overall cohort (p=0.03), but this effect was driven by the low-risk subgroup.  
- **Conclusion of the study**: Longer treatment duration (NTDR ≥33%) is an adverse factor *specifically in low-risk patients*.  

The evidence is strong for low-risk patients but not generalizable to all risk groups. The study explicitly identifies treatment duration as harmful in low-risk cases but not in others.

**3. Conclusion**  
The answer depends on the patient's risk group. Since the question does not specify a risk group, the study shows that treatment duration *does* affect outcomes in **some** prostate cancer patients (low-risk subgroup). However, it does not universally apply to all patients. The abstract’s conclusion highlights this subgroup-specific effect, so the answer leans toward "yes" because the study confirms a significant association in a relevant subgroup, even if not universal.

**4. Final Answer:**  
**My final choice is: "yes"**
Qwen selected: yes

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether treatment duration (specifically, elapsed time during radiotherapy) impacts outcomes for prostate cancer patients. Key elements to identify in the abstract include:  
- How treatment duration was measured (NTDR: nontreatment day ratio).  
- Association between NTDR and biochemical failure (FFBF).  
- Differences in outcomes across risk groups (low, intermediate, high).  

**2. Evidence Evaluation**  
- The study found that in **low-risk patients**, a higher NTDR (≥33%, indicating longer treatment duration with more breaks) significantly reduced 10-year FFBF (82% vs. 57%, *p* = 0.0019). NTDR was an independent predictor of FFBF on multivariate analysis.  
- No significant effect was observed in intermediate/high-risk groups or when all groups were combined.  
- The conclusion explicitly states that prolonged treatment duration (NTDR ≥33%) is detrimental for low-risk patients and should be avoided.  

**3. Conclusion**  
The evidence confirms that treatment duration affects outcomes **specifically in low-risk prostate cancer patients**. However, the effect is not universal across all risk groups. Since the question does not specify risk stratification, the answer must account for the study’s mixed findings. While the abstract demonstrates a clear effect in a subset (low-risk), the lack of significance in other groups introduces uncertainty for the broader population.  

**4. Final Answer**  
**My final choice is: yes**  
*Rationale:* The study identifies a statistically significant and clinically meaningful impact of treatment duration (via NTDR) on biochemical failure in low-risk patients. Even though the effect is restricted to this subgroup, the question does not exclude risk-specific considerations. Thus, the answer is "yes," as treatment duration demonstrably affects outcomes in at least one defined cohort.
DeepSeek selected: yes

Initial consensus: All models selected yes